The Society for Immunotherapy of Cancer Consensus Statement on Tumour Immunotherapy for the Treatment of Cutaneous Melanoma

A clinical practice guideline for the treatment of cutaneous melanoma patients with tumour immunotherapy. The guideline examines the clinical application of immunotherapy with interferon‐α2b, pegylated‐interferon‐α2b, interleukin‐2 (IL‐2) and ipilimumab for high-risk, advanced-stage cancer. Outcomes of interest include decreasing the adverse effects of depression and improved therapeutic strategies with immunotherapy and standard radiation.